Alzheimer Disease

The American Academy of Neurology issued a position statement for mental health professionals, warning them to carefully discuss the benefits and known harms of aducanumab.

Decades of efforts to find effective medical treatments for dementia and Alzheimers disease have largely failed. Would a public health approach be more effective?

What advice can clinicians give patients to lower their overall risk for neurodegenerative diseases?

A new study finds amyloid plaques accelerate the breakup of neurotransmitters, worsening neurodegenerative diseases like Alzheimer disease.

More potential good news for treating Alzheimer disease, as an 18-month open-label extension for lecanemab allows for its breakthrough status.

Although the new drug aducanumab has grabbed all the headlines, the future of Alzheimer treatment may be just as much about public health campaigns as it is about psychopharmacology. In this episode of Psych Pearls, we find out why.

Apathy occurs throughout the spectrum of neurocognitive disorders, but it is easy to mistake for other conditions, like depression. How can clinicians identify apathy, and treat it?

Following criticism for its wide-labeled June approval, the FDA has decided to narrow the patient recommendation for aducanumab.

How can volunteering to play video games help brain research?

Donanemab for the treatment of Alzheimer disease has received Breakthrough Therapy designation from the FDA.

The FDA approval of aducanumab has given hope to millions of patients with Alzheimer disease—but will it live up to the hype?

What effect will aducanumab have on Alzheimer disease treatment?

This one-of-a-kind Alzheimer disease treatment targets the amyloid beta plaques in the brain, potentially slowing cognitive decline.

Gene expressions in microglia cells may explain why some of them are ineffective and allow dementia to progress.

This monoclonal antibody showed significant slowing of decline in patients with Alzheimer disease.

Aducanumab is named 1 of the 5 “Drugs to Watch” for 2021.

A study on a new Alzheimer disease vaccine lacks concrete numbers.

Cognitive impairment is not always associated with dementia. For this reason, a full comprehensive history is an integral component of any assessment. Take the quiz to learn more.

A new formulation of dexmedetomidine meets primary and secondary endpoints in recently completed study.

A new treatment for hallucinations and delusions in individuals with Alzheimer disease may be on the horizon.

New developments in Alzheimer disease treatment and research.

The Lumipulse® G β-Amyloid Ratio in vitro diagnostic test was filed for 510(k) premarket clearance.

A new study associates a gene that facilitates neuron communication in the nervous system with memory loss.

Patients with chronic inflammatory diseases, especially rheumatoid arthritis, are at 800% increased risk for developing Alzheimer disease compared to the general population. A new treatment is in the works to combat this inflammation.

Good news in the fight against Alzheimer disease, with major progress in new, innovative treatments.